A. Schäfer

Eligibility for Baroreflex Activation Therapy and medication adherence in patients with apparently resistant hypertension

Mark Lipphardt, M. Wallbach, M. Koziolek, 2021, Journal of clinical hypertension.

Impact of medication adherence on the efficacy of Baroreflex activation therapy

M. Wallbach, S. Lüders, M. Koziolek, 2022, Journal of clinical hypertension.

Effect of baroreflex activation therapy on renal sodium excretion in patients with resistant hypertension

G. Müller, Mark Lipphardt, M. Wallbach, 2019, Clinical Research in Cardiology.

Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension

H. Dihazi, B. Ratliff, Mark Lipphardt, 2020, Journal of clinical medicine.

Urinary Dickkopf-3 (DKK3) Is Associated with Greater eGFR Loss in Patients with Resistant Hypertension

H. Dihazi, M. Wallbach, S. Lüders, 2023, Journal of clinical medicine.

Effect of baroreflex activation therapy on dipping pattern in patients with resistant hypertension

M. Wallbach, M. Koziolek, Ellen Born, 2022, Journal of clinical hypertension.

[Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms].

M. Reuter, W. Knapp, A. Wagner, 1997, Nuklearmedizin. Nuclear medicine.

Case Report: High-dose immunoglobulins prior to plasma exchange in severe pulmonary renal syndrome

P. Korsten, M. Schnelle, B. Tampe, 2023, Frontiers in Immunology.